For over 20 years it has been known that people with systemic lupus erythematosis are at much higher risk of succumbing to atherosclerotic vascular disease. The precise etiology is not known but the available data suggests that the usual mechanics of & risk factors for arteriosclerosis are operative. These are probably enhanced by other factors such as corticosteroid use and the disease itself. The means of preventing ASVD complication (primary prevention) or their recurrence (secondary prevention) have not been studied. Their proposal for a placebo controlled clinical trials of 3 strategies; to establish proof of concept using a surrogate endpoint a risk model based on the Framingham study. Each arm of the study represents a clinically relevant strategy and incorporates in a styled approach with increasingly proven medications, all are delivered by a novel telephonic risk factor management system. This pilot study will develop important data necessary for a large definitive RCT using clinically endpoints.
Showing the most recent 10 out of 444 publications
